Mountain View, CA, United States of America

Jinnuo Han

This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: Leland Stanford Junior University. Active years: 2015-2018.

USPTO Granted Patents = 2 

% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 2

Forward Citations = 10(Granted Patents)


Company Filing History:


Years Active: 2015-2018

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Jinnuo Han: Innovator in Embryo Viability Assessment

Introduction

Jinnuo Han is a notable inventor based in Mountain View, CA (US). He has made significant contributions to the field of reproductive biology through his innovative research and patents. With a total of 2 patents, Han's work focuses on enhancing the viability of mammalian embryos and oocytes.

Latest Patents

Han's latest patents include groundbreaking methods for determining the viability of mammalian embryos and potential embryos generated from oocytes. These methods involve applying a mechanical stimulus to the embryo or oocyte, detecting the temporal response, and deriving measurements indicative of viability. Additionally, his patents provide methods for selecting embryos for transfer and enhancing the viability of embryos or oocytes.

Career Highlights

Jinnuo Han is affiliated with Leland Stanford Junior University, where he conducts his research. His work has garnered attention for its potential applications in reproductive medicine and embryology.

Collaborations

Han collaborates with esteemed colleagues, including Livia Zarnescu and David B Camarillo, to further advance his research in the field.

Conclusion

Jinnuo Han's innovative contributions to embryo viability assessment highlight his role as a leading inventor in reproductive biology. His patents pave the way for advancements in the selection and enhancement of embryos, showcasing the importance of mechanical biomarkers in this critical area of research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…